52
Participants
Start Date
May 20, 2019
Primary Completion Date
April 4, 2022
Study Completion Date
April 4, 2022
SAR441236
Administered by intravenous (IV) infusion(s) or subcutaneous (SC) injection(s)
Placebo
Administered by intravenous (IV) infusion(s) or subcutaneous (SC) injection(s)
Weill Cornell Chelsea CRS, New York
Weill Cornell Uptown CRS, New York
University of Rochester Adult HIV Therapeutic Strategies Network CRS, Rochester
University of Pittsburgh CRS, Pittsburgh
Penn Therapeutics, CRS, Philadelphia
Chapel Hill CRS, Chapel Hill
Alabama CRS, Birmingham
Vanderbilt Therapeutics (VT) CRS, Nashville
Ohio State University CRS, Columbus
Case Clinical Research Site, Cleveland
Cincinnati Clinical Research Site, Cincinnati
Northwestern University CRS, Chicago
Rush University CRS, Chicago
University of Colorado Hospital CRS, Aurora
UCLA CARE Center CRS, Los Angeles
UCSD Antiviral Research Center CRS, San Diego
Ucsf Hiv/Aids Crs, San Francisco
Massachusetts General Hospital CRS (MGH CRS), Boston
Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS, Boston
Washington University Therapeutics (WT) CRS, St Louis
New Jersey Medical School Clinical Research Center CRS, Newark
The Miriam Hospital Clinical Research Site (TMH CRS) CRS, Providence
University of Washington Positive Research CRS, Seattle
Collaborators (1)
Sanofi
INDUSTRY
ModeX Therapeutics, An OPKO Health Company
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH